Health latest study: SMA patients continue to benefit from Nosina sodium injection

The new data include additional follow-up for nearly a year for THE STUDY PARTICIPANTS IN THE NURTURE STUDYAs of February 2020, all patients receiving treatment (n-25; median age is 3.8 years) are viable and do not require permanent ventilationWithout treatment, most children with SMA-Type I live less than 2 years on averageIn addition, all children who reached the milestone of independent walking (many at the normal age group) maintained this ability after the initial ability to walk independently until the last follow-up, A SECOND-STAGE NON-BLIND STUDY OF 25 PRE-SYMPTOM SMA PATIENTS (MOST LIKELY DEVELOPING SMA-I OR TYPE II) WHO WERE GENETICALLY DIAGNOSED WITH SMA AND TREATED WITH THE FIRST DOSE OF NOSINA SODIUM INJECTION BEFORE 6 WEEKS OF AGE ARE CURRENTLY UNDER WAYThe study was extended by an additional three years to enable the health to assess the longer-term efficacy and safety of receiving Nosina sodium injections until the age of 8, and to further understand the impact of early treatmentMore results from the latest interim analysisas of February 2020 show thatall study participants who had previously been able to walk under assisted (92 percent) and walk independently (88 percent) maintained this ability for the 11 months after the last data was releasedduring the 11-month follow-up, a child was given the ability to walk under assisted mobility (increasing this percentage to 96 percent of all study participants) and reached the highest score on the Chop-INTEND scale for infant neuromuscular disease tests at Pennsylvania Children's Hospital, raising the total number of study participants with the highest score to 21 out of 25 (84 percent)patients with two copies of SMN2 were able to score and make progress in the extended Hammersmith Functional Motion Scale (HFMSE), which is unusual for the natural history of the diseasethe Nosina sodium injection was well tolerated and no new safety issues were found during the extended follow-up periodNo children have withdrawn from the study because of adverse events associated with treatment(The original text has a cut)